MX352599B - Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. - Google Patents
Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.Info
- Publication number
- MX352599B MX352599B MX2013012393A MX2013012393A MX352599B MX 352599 B MX352599 B MX 352599B MX 2013012393 A MX2013012393 A MX 2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A MX 352599 B MX352599 B MX 352599B
- Authority
- MX
- Mexico
- Prior art keywords
- protein tyrosine
- type protein
- tyrosine phosphatase
- antibody
- human receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011101752 | 2011-04-28 | ||
| PCT/JP2012/061795 WO2012148003A1 (en) | 2011-04-28 | 2012-04-27 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012393A MX2013012393A (es) | 2014-04-30 |
| MX352599B true MX352599B (es) | 2017-11-30 |
Family
ID=46147004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012393A MX352599B (es) | 2011-04-28 | 2012-04-27 | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9803026B2 (OSRAM) |
| EP (2) | EP3232202B1 (OSRAM) |
| JP (2) | JP6001557B2 (OSRAM) |
| KR (1) | KR101873614B1 (OSRAM) |
| CN (1) | CN103703372B (OSRAM) |
| AU (2) | AU2012248158C1 (OSRAM) |
| CA (1) | CA2834243C (OSRAM) |
| ES (2) | ES2788183T3 (OSRAM) |
| HU (2) | HUE054211T2 (OSRAM) |
| IL (1) | IL229127A (OSRAM) |
| MX (1) | MX352599B (OSRAM) |
| PL (2) | PL2702412T3 (OSRAM) |
| PT (2) | PT3232202T (OSRAM) |
| RU (2) | RU2715642C2 (OSRAM) |
| SG (3) | SG10201503257WA (OSRAM) |
| WO (1) | WO2012148003A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20151261T1 (hr) | 2007-07-02 | 2016-01-01 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka |
| PL2702412T3 (pl) * | 2011-04-28 | 2018-01-31 | Sbi Biotech Co Ltd | Przeciwciało przeciwko ludzkiej białkowej fosfatazie tyrozynowej typu receptorowego |
| BR112014000765A2 (pt) | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | agentes de ligação a rspo e seus usos |
| MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
| EP2877494B1 (en) * | 2012-07-23 | 2020-07-15 | La Jolla Institute for Allergy and Immunology | Ptprs and proteoglycans in autoimmune disease |
| WO2015117199A1 (en) * | 2014-02-04 | 2015-08-13 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| US11160873B2 (en) * | 2014-02-04 | 2021-11-02 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| JP2017528523A (ja) | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| RU2698205C2 (ru) * | 2014-12-18 | 2019-08-23 | Ф. Хоффманн-Ля Рош Аг | Способ определения антител, вызывающих комплемент-зависимую цитотоксичность |
| JP7251792B2 (ja) * | 2017-03-23 | 2023-04-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗Ｃ５ａ抗体とその使用 |
| US20200132673A1 (en) * | 2017-03-24 | 2020-04-30 | The Regents Of The University Of California | Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom |
| WO2019028182A2 (en) * | 2017-08-01 | 2019-02-07 | Remd Biotherapeutics, Inc. | TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40) |
| CN118955712A (zh) * | 2018-07-25 | 2024-11-15 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| KR20220075371A (ko) * | 2019-10-04 | 2022-06-08 | 앨버트 아인슈타인 컬리지 오브 메디신 | 면역계의 억제 수용체인 kir3dl3 및 그의 용도 |
| AU2022317144A1 (en) | 2021-07-30 | 2024-01-25 | The Regents Of The University Of California | Ptprs in autoimmunity |
| CN114426582B (zh) * | 2022-01-07 | 2022-11-25 | 陕西脉元生物科技有限公司 | 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用 |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
| AU2024231685A1 (en) * | 2023-03-03 | 2025-09-25 | Case Western Reserve University | Cell adhesion molecule targeted immunotherapies |
| CN118994384B (zh) * | 2024-08-09 | 2025-09-26 | 陕西脉元生物科技有限公司 | 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法 |
| CN119874900B (zh) * | 2025-03-06 | 2025-10-17 | 吉林大学 | 一种单克隆抗体及其在制备治疗肿瘤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0721352A4 (en) | 1993-10-01 | 1998-07-01 | Univ New York | NEW PHOSPHOTYROSINE PHOSPHATASE - -g (s) WITH RECEPTOR FUNCTION |
| JP4498136B2 (ja) | 2002-08-01 | 2010-07-07 | Ｓｂｉバイオテック株式会社 | マウスインターフェロン産生細胞の検出方法 |
| WO2004081047A1 (ja) * | 2003-03-14 | 2004-09-23 | Taisho Pharmaceutical Co., Ltd. | モノクローナル抗体及びこれを産生するハイブリドーマ |
| CA2561073C (en) | 2004-03-27 | 2014-01-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US20070134234A1 (en) | 2005-09-29 | 2007-06-14 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| WO2009003274A1 (en) | 2007-06-29 | 2009-01-08 | The Hospital For Sick Children | Susceptibility gene for inflammatory bowel disease |
| ES2796111T3 (es) * | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| WO2011022462A2 (en) * | 2009-08-18 | 2011-02-24 | President And Fellows Of Harvard College | Neural regeneration |
| EP2531859A4 (en) * | 2010-02-02 | 2013-07-31 | Jolla Inst Allergy Immunolog | Compositions and methods of modulating receptor protein tyrosine phosphatases |
| PL2702412T3 (pl) * | 2011-04-28 | 2018-01-31 | Sbi Biotech Co Ltd | Przeciwciało przeciwko ludzkiej białkowej fosfatazie tyrozynowej typu receptorowego |
-
2012
- 2012-04-27 PL PL12722557T patent/PL2702412T3/pl unknown
- 2012-04-27 WO PCT/JP2012/061795 patent/WO2012148003A1/en not_active Ceased
- 2012-04-27 RU RU2017118262A patent/RU2715642C2/ru active
- 2012-04-27 MX MX2013012393A patent/MX352599B/es active IP Right Grant
- 2012-04-27 HU HUE17174348A patent/HUE054211T2/hu unknown
- 2012-04-27 SG SG10201503257WA patent/SG10201503257WA/en unknown
- 2012-04-27 EP EP17174348.7A patent/EP3232202B1/en active Active
- 2012-04-27 SG SG10202108240VA patent/SG10202108240VA/en unknown
- 2012-04-27 HU HUE12722557A patent/HUE034752T2/en unknown
- 2012-04-27 JP JP2013549652A patent/JP6001557B2/ja active Active
- 2012-04-27 CN CN201280020580.XA patent/CN103703372B/zh active Active
- 2012-04-27 PT PT171743487T patent/PT3232202T/pt unknown
- 2012-04-27 PL PL17174348T patent/PL3232202T3/pl unknown
- 2012-04-27 US US14/113,904 patent/US9803026B2/en active Active
- 2012-04-27 AU AU2012248158A patent/AU2012248158C1/en active Active
- 2012-04-27 SG SG2013079066A patent/SG194614A1/en unknown
- 2012-04-27 KR KR1020137028325A patent/KR101873614B1/ko active Active
- 2012-04-27 ES ES17174348T patent/ES2788183T3/es active Active
- 2012-04-27 RU RU2013152816/10A patent/RU2013152816A/ru not_active Application Discontinuation
- 2012-04-27 ES ES12722557.1T patent/ES2638088T3/es active Active
- 2012-04-27 PT PT127225571T patent/PT2702412T/pt unknown
- 2012-04-27 CA CA2834243A patent/CA2834243C/en active Active
- 2012-04-27 EP EP12722557.1A patent/EP2702412B1/en active Active
-
2013
- 2013-10-28 IL IL229127A patent/IL229127A/en active IP Right Grant
-
2016
- 2016-09-01 JP JP2016170634A patent/JP6412072B2/ja active Active
- 2016-11-23 AU AU2016262677A patent/AU2016262677B2/en active Active
-
2017
- 2017-10-06 US US15/726,669 patent/US10730955B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013012393A (es) | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. | |
| CY1123145T1 (el) | Anti-cd40 αντισωματα | |
| NI201400019A (es) | Anticuerpo anti-alfabetatcr | |
| PH12017502161A1 (en) | Anti-cd40 antibodies and uses thereof | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
| CR20140146A (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| MX347454B (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| WO2013115410A3 (en) | Anti-phospholipase d4 antibody | |
| EP3029069A4 (en) | Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof | |
| EA201491107A1 (ru) | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3 | |
| TN2015000277A1 (en) | Bmp-6 antibodies | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| SG11201810779PA (en) | Method for screening antibody using patient-derived tumor spheroids | |
| GB201207155D0 (en) | Antibodies | |
| EP4524563A3 (en) | Flow based assays for therapeutics | |
| UA111372C2 (uk) | ФРАГМЕНТ Fab' АНТИТІЛА ПРОТИ NGF ЛЮДИНИ | |
| TH142231A (th) | แอนตี้บอดี้สำหรับรีเซพเตอร์ 3 ของปัจจัยการเจริญเติบโตของหนังกำพร้า (her3) | |
| CR20150351A (es) | Proteinas de union al antígeno bcma | |
| TN2013000045A1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |